GRx+Biosims 2018 | Association for Accessible Medicines

GRx+Biosims 2018

September 5-7, 2018
Hilton Baltimore
Baltimore, MD

Uniting the power of innovation, science and policy to increase patient access to generic and biosimilar medicines.

AAM listened to our members and conference attendees and has created the ultimate event for the industry. We combined all our conferences — with the exception of the annual meeting — into the single best opportunity to hear directly from government officials, learn best practices and connect with peers in the generics and biosimilars industry.

GRx+Biosims is the name of the combined event that replaces FallTech, Leading on Biosimilars and CMC Workshop. The program will be comprehensive and the speakers are the top in their field. Whatever your interests, you will find what you need at GRx+Biosims. With science, policy and the market in constant flux, it is critical to come together as an industry to “engineer the future of generic and biosimilar medicines.”

View our meeting registration fees.

Be part of the GRx+Biosims 2018 Exposition.

Inquire about our sponsorship opportunities.

Follow the event on Twitter: #GRxBiosims



View More Videos


Hotel Information

Hilton Baltimore
401 W Pratt St.
Baltimore, MD 21201

Reservations must be made directly with the Hilton Baltimore by calling 1-800-445-8667 or online by clicking here. Please refer to the SRIP code "ATC" or “GRx+Biosims” to obtain the preferred rate. Only a limited number of preferred rate rooms are available. The preferred rate cut off date is August 8, 2018. After this date or after the preferred rate rooms are sold out, rooms are subject to hotel rates and availability.

GRx+Biosims Sponsors

GRx+Biosims Sponsors

Subscribe for GRx+Biosims Updates

Please fill out the form below to receive the latest event information about key speakers, sponsorship opportunities and exhibiting.

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.